Zeni Kharel

Zeni Kharel

Auto-generated profile, based on publicly available information

Zeni Kharel

Division of Hematology/Oncology Rochester General Hospital Rochester New York USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 March 2020 in Cureus
Verified
Journal Article
Open access
PDF file
HKHimal Kharel
Himal Kharel
NPNishan B. Pokhrel
Nishan B. Pokhrel
RGRakesh Ghimire
Rakesh Ghimire
ZKZeni Kharel
Zeni Kharel
The benefits of atropine in the treatment of acute organophosphate (OP) poisoning has been well established, while that of oximes is still uncertain. Pralidoxime is the most often used oxime worldwide. In vitro experiments have consistently shown that oximes are effective reactivators of human acetylcholinesterase enzyme, inhibited by OP compounds. However, the clinical benefit of pralidoxime is still unclear. A recent meta-analysis has found that pralidoxime provides no significant improvement in outcome and rather may cause harm while increasing the economic burden in low-income communities where its use is the most prevalent. This study aimed to provide an updated evaluation of the efficacy of pralidoxime in addition to atropine alone in the treatment of patients with acute OP poisoning in terms of mortality, need for ventilator support, and the incidence of intermediate syndrome. The intermediate syndrome is a clinical syndrome that occurs 24 to 96 hours after the ingestion of an OP compound and is characterized by prominent weakness of neck flexors, muscles of respiration, and proximal limb muscles. We searched MEDLINE, EMBASE, CENTRAL, and ClinicalTrials.gov databases until January 2019 for randomized controlled trials (RCTs) in the English language that evaluated the use of pralidoxime in individuals of any age, gender or nationality presenting with an alleged history of OP intake. The primary outcome was mortality. Secondary outcomes were the need for ventilator support and the incidence of intermediate syndrome. The risk of bias in included studies was assessed using the tool recommended by the Cochrane Handbook of Systematic Review of Interventions. Treatment/control differences in these outcomes across included studies were combined using risk ratios (RR). Six randomized controlled trials (n = 646) fulfilled the inclusion criteria, including one further trial missed from the most recent systematic review. The risk of bias varied across studies, with Eddleston 2009 being of the lowest risk and Cherian 2005 being of high risk. The risk of mortality (RR = 1.53, 95% confidence interval (CI) 0.97 to 2.41, P = 0.07) and the need for ventilator support (RR = 1.29, 95% CI 0.97 to 1.71, P = 0.08) were not significantly different between the pralidoxime and the control group. There was a significant increase in the incidence of intermediate syndrome in the pralidoxime group (RR = 1.63; 95% CI 1.01 to 2.62, P = 0.04). Based on our meta-analysis of the available RCTs, pralidoxime was not shown to be beneficial in patients with acute OP poisoning. Our findings are consistent with the other literature.

22 April 2024 in Haemophilia
Verified
Journal Article
Closed access
PDF file
ZKZeni Kharel
Zeni Kharel
RPRajiv K. Pruthi
Rajiv K. Pruthi
PKPeter Kouides
Peter Kouides
RRRobin Reid
Robin Reid

19 April 2024 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
ZKZeni Kharel
Zeni Kharel
HKHimal Kharel
Himal Kharel
PPPradyumna D. Phatak
Pradyumna D. Phatak

20 November 2024 in Personalized Medicine
Verified
Journal Article
Closed access
ZKZeni Kharel
Zeni Kharel
SSSarah Stanford
Sarah Stanford
LHLauryn E Hemminger
Lauryn E Hemminger
TSTyler Schmidt
Tyler Schmidt
SHSara J Hardy
Sara J Hardy
ADAjay Dhakal
Ajay Dhakal
Accepted at SABCS 2023, poster presented at SABCS 2023We report the efficacy of trastuzumab deruxtecan (T-DXd) in treating human epidermal growth factor receptor 2 (HER2) low, type ID leptomeningeal breast cancer (LMD) (with positive cerebrospinal fluid [CSF] cytology and hydrocephalus as the only abnormal imaging finding) and the diagnostic and monitoring utilization of a novel microfluidic platform called CNSide™. Breast cancer LMD is associated with poor prognosis, and effective treatments are lacking. Our case highlights two crucial aspects related to the treatment and monitoring of breast cancer LMD. First, T-DXd was chosen based on immunocytochemistry (IHC) data from CSF malignant cells and follow-up revealed effectiveness of T-DXd in treating HER2-low LMD. While the efficacy of T-DXd has been established in treating metastatic HER2-low breast cancer, our case represents, to our knowledge, the first demonstration of T-DXd's effectiveness in HER2-low breast cancer LMD. Second, since this is type 1D LMD with absence of unequivocal measurable radiological disease in both the central nervous system (CNS) and extra-CNS, we employed a novel microfluidic CSF assay to monitor disease response. This novel assay outperformed standard CSF cytology in our case. There is an urgent need to develop CSF tumor cell assessment tool that surpasses the capabilities of conventional CSF cytology.

5 April 2025 in American Journal of Hematology
Verified
Journal Article
Closed access
ZKZeni Kharel
Zeni Kharel
NRNicole Jean Rubin
Nicole Jean Rubin
RDRachel J. David
Rachel J. David
PKPeter Kouides
Peter Kouides

1 January 2024 in Research Square
Verified
Preprint
Open access
PDF file
ZKZeni Kharel
Zeni Kharel
HKHimal Kharel
Himal Kharel
PPPradyumna D. Phatak
Pradyumna D. Phatak
A 58-year-old female was found to have hyperferritinemia (Serum ferritin:1683 ng/mL) during work-up for mild normocytic anemia. Transferrin saturation was low normal. Genetic analysis for hereditary hemochromatosis(HH) related HFE mutations showed absence of the common mutations (C282Y, H63D and S65C). Magnetic resonance imaging (MRI) abdomen showed evidence of hepatic iron deposition. Liver biopsy showed 4 + hepatic iron deposition without any evidence of steatosis or fibrosis. Quantitative liver iron was elevated at 348.3 µmol/g dry liver weight [Reference range(RR): 3–33 µmol/g dry liver weight]. She was presumptively diagnosed with tissue iron overload, cause uncertain. A diagnosis of ferroportin disease(FD) was entertained but the distribution of iron in the liver was largely parenchymal making this atypical. She was treated with intermittent phlebotomy for over a decade with poor tolerance due to worsening microcytic anemia. During the course of treatment, her ferritin level decreased. Over the past 1.5 years, she developed progressively worsening neurocognitive decline. MRI brain showed areas of susceptibility involving basal ganglia, midbrain and cerebellum raising suspicion for metabolic deposition disease. Neuroimaging findings led to testing for serum copper and ceruloplasmin levels which were both found to be severely low. The diagnosis of aceruloplasminemia was ultimately made. The biochemical triad of hyperferritinemia, low/normal transferrin saturation and microcytic anemia should raise the possibility of aceruloplasminemia. Since neurological manifestations are rare in most inherited iron overload syndromes, neurological symptoms in a patient with tissue iron overload should prompt consideration of aceruloplasminemia as a differential diagnosis.